Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA has initiated a rights issue aiming to raise up to NOK 52 million by offering between 3,658,000 to 20,732,010 new shares at NOK 2.50 each, accompanied by warrants. The subscription period for this issue ends on July 8, 2024, with the possibility of oversubscription. The biotech company is known for developing RNA therapeutics and a cancer vaccine, currently undergoing clinical trials.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
